Trials / Conditions / Childhood Choroid Plexus Tumor

Childhood Choroid Plexus Tumor

13 registered clinical trials studyying Childhood Choroid Plexus Tumor.

Status	Trial	Sponsor	Phase
Terminated	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervou NCT02255461	Pediatric Brain Tumor Consortium	Phase 1
Withdrawn	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452	Sue O'Dorisio	N/A
Terminated	Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With NCT01987596	Barbara Ann Karmanos Cancer Institute	Phase 3
Terminated	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500	National Cancer Institute (NCI)	Phase 1
Completed	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335	National Cancer Institute (NCI)	Phase 1
Completed	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880	National Cancer Institute (NCI)	Phase 1
Completed	Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973	National Cancer Institute (NCI)	Phase 1
Completed	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780	National Cancer Institute (NCI)	Phase 1
Completed	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963	National Cancer Institute (NCI)	Phase 1
Completed	Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078	Children's Oncology Group	Phase 2